DDInter1144 DDInter1376
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard.[A261150, A261155] Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is also used to treat uveal melanoma with unresectable hepatic metastases.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Melphalan {u} (Compound) resembles {v} (Compound) L-Phenylalanine
Melphalan {u} (Compound) resembles {v} (Compound) Levodopa
Melphalan {u} (Compound) treats {v} (Disease) ovarian cancer
Melphalan {u} (Compound) binds {v} (Gene) SLC7A5
Melphalan {u} (Compound) upregulates {v} (Gene) DDB2
Melphalan {u} (Compound) is included by {v} (Pharmacologic Class) Alkylating Activity
Melphalan {u} (Compound) causes {v} (Side Effect) Radiation myelopathy
Melphalan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Norfloxacin
Melphalan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Melphalan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Efalizumab
Melphalan (Compound) resembles L-Phenylalanine (Compound)
Melphalan (Compound) resembles Levodopa (Compound)
Melphalan (Compound) treats ovarian cancer (Disease)
Melphalan (Compound) binds SLC7A5 (Gene)
Melphalan (Compound) upregulates DDB2 (Gene)
Melphalan (Compound) is included by Alkylating Activity (Pharmacologic Class)
Melphalan (Compound) causes Radiation myelopathy (Side Effect)
Melphalan may cause a minor interaction that can limit clinical effects when taken with Norfloxacin
Melphalan may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Melphalan may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab